Efficacy and safety of valgancyclovir as preemptive therapy for the prevention of cytomegalovirus disease in solid organ transplant recipients.

Díaz-Pedroche, C; Lumbreras, C; Del Valle, P; San Juan, R; Hernando, S; Folgueira, D; Andrés, A; Delgado, J; Meneu, J C; Morales, J M; Moreno, E; Aguado, J M

Díaz-Pedroche, C; Lumbreras, C; Del Valle, P; San Juan, R; Hernando, S; Folgueira, D; Andrés, A; Delgado, J; Meneu, J C; Morales, J M; Moreno, E; Aguado, J M.

Affiliation

Díaz-Pedroche C; Infectious Diseases Unit, Department of Digestive Surgery and Abdominal Organs Transplantation, University Hospital 12 de Octubre, Madrid, Spain. carmendiaz@ya.com

Transplant Proc ; 37(9): 3766-7, 2005 Nov.

Article in En | MEDLINE | ID: mdl-16386532

Subject(s)

Antiviral Agents/therapeutic use; Cytomegalovirus Infections/prevention & control; Ganciclovir/analogs & derivatives; Postoperative Complications/prevention & control; Antigens, Viral/blood; Cytomegalovirus/isolation & purification; Ganciclovir/therapeutic use; Heart Transplantation; Humans; Kidney Transplantation; Liver Transplantation; Postoperative Complications/virology; Valganciclovir

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Postoperative Complications / Ganciclovir / Cytomegalovirus Infections Limits: Humans Language: En Journal: Transplant Proc Year: 2005 Document type: Article Affiliation country: Spain Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links